Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
We conducted a systematic review and meta-analysis to evaluate the effect of Berberine on glucose in patients with type 2 diabetes mellitus and identify potential factors may modifying the hypoglycemic effect. We searched PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database to identify randomized controlled trials that investigated the effect of Berberine. We calculated weighted mean differences (WMD) and 95% confidence interval (CI) for fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and glycated haemoglobin (HbA1c) levels. Twenty-eight studies were identified for analysis, with a total of 2,313 type 2 diabetes mellitus (T2DM) patients. The pool data showed that Berberine treatment was associated with a better reduction on FPG (WMD = -0.54 mmol/L, 95% CI: -0.77 to -0.30), PPG (WMD = -0.94 mmol/L, 95% CI: -1.27 to -0.61), and HbA1c (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15) than control groups. Subgroup-analyses indicated that effects of Berberine on blood glucose became unremarkable as the treatment lasted more than 90 days, the daily dosage more than 2 g/d and patients aged more than 60 years. The efficiency of Berberine combined with hypoglycaemics is better than either Berberine or hypoglycaemic alone. The dosage and treatment duration of Berberine and patients' age may modify the effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573 · cited 3×
“2008 [15] Randomized, double-blind, placebocontrolled and multiple-center trial 58/52 Newly diagnosed 51 ± 9/51 ± 10 Berberine/ placebo 0.”
BackgroundMethodSelf-citationLan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.09.049 · Cited by 458 · cited 5×
“Another systematic literature review added 14 studies, but just four RCT studies focused on T2DM patients and others assessed the effect of Berberine on hyperlipidemia and hypertension patients [9].”
BackgroundMethodResultInfluentialBerberine in the treatment of type 2 diabetes mellitus: A systemic review and meta-analysis
Dong, H., Wang, N., Zhao, L., & Lu, F. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/591654 · Cited by 225
Cited by
Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y., & Liu, W. J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/2074610 · Cited by 110
Ye, Y., Liu, X., Wu, N., Han, Y., Wang, J., Yu, Y., & Chen, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.653887 · Cited by 109
“Recently, basic research has proven that berberine can be used to lower the blood glucose level (Liang et al., 2019), improve insulin resistance (Lou et al.”
BackgroundMing, J., Yu, X., Xu, X., Wang, L., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00942-7 · Cited by 52
“This was consistent with the results from previous clinical trials [30, 31], which indicated that berberine treatment was associated with different degrees of reduction on FPG, 2-hr PPG and HbA1c.”
ResultSelf-citationPanigrahi, A., & Mohanty, S. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01442-y · Cited by 30
Zamani, M., Zarei, M., Nikbaf-Shandiz, M., Hosseini, S., Shiraseb, F., & Asbaghi, O. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1013055 · Cited by 28
Li, M., Liu, Y., Qiu, Y., Zhang, J., Zhang, Y., Zhao, Y., Jia, Q., & Li, J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113899 · Cited by 21
Self-citationCicero, A. F. G., Kennedy, C., Knežević, T., Bove, M., Georges, C. M. G., Šatrauskienė, A., Toth, P. P., & Fogacci, F. (2021) · Nutrients · doi:10.3390/nu13020638 · Cited by 20
“Policosanols, together with berberine, may also be responsible for the reduction in FPG levels observed after dietary supplementation with Armolipid Plus® [56].”
BackgroundWang, J., Bi, C., Xi, H., & Wei, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1455534 · Cited by 13
Metadata
- Authors
- Liang, Y., Xu, X., Yin, M., Zhang, Y., Huang, L., Chen, R., & Ni, J.
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2019
- Volume
- 66
- Issue
- 1
- Pages
- 51-63
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W2899175683
- Cited by
- 129
- References
- 3
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.